Therapy Areas: Hereditary Disorders
Endo Ventures signs development and distribution contract with Quoin Pharmaceuticals
18 July 2022 -

Ireland-based Endo International plc (NASDAQ: ENDP) announced on Friday that its subsidiary Endo Ventures Limited has signed contract with Quoin Pharmaceuticals Inc. (NASDAQ: QNRX), an Israel-based specialty pharmaceutical company, for the development, registration, supply, commercialisation and distribution of Quoin's QRX003 on an exclusive basis in Canada.

QRX003 is Quoin's lead product for Netherton syndrome, a rare, hereditary disorder.

If QRX003 receives approval, Paladin Labs Inc., an Endo operating company, will handle all commercial activities in Canada. Presently, Paladin is expecting to introduce the product in Canada in 2025.



Related Headlines